![More drug access needed for breast cancer patients with gBRCA, PIK3CA mutation < Policy < Article - KBR More drug access needed for breast cancer patients with gBRCA, PIK3CA mutation < Policy < Article - KBR](https://cdn.koreabiomed.com/news/photo/202112/12865_13295_2255.jpg)
More drug access needed for breast cancer patients with gBRCA, PIK3CA mutation < Policy < Article - KBR
![PIQRAY (alpelisib) Tablets | Price & Cost | Pharma Network Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA PIQRAY (alpelisib) Tablets | Price & Cost | Pharma Network Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA](https://medvitaz.com/wp-content/uploads/2020/12/piqray.jpg)
PIQRAY (alpelisib) Tablets | Price & Cost | Pharma Network Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
![Piqray Alpelisib 300 mg Tablets at Rs 154000/box | Alpelisib Tablet in Chandigarh | ID: 2852878688412 Piqray Alpelisib 300 mg Tablets at Rs 154000/box | Alpelisib Tablet in Chandigarh | ID: 2852878688412](http://5.imimg.com/data5/SELLER/Default/2023/10/356092207/AT/RY/GF/201574836/piqray-alpelisib-tablets-500x500.jpeg)